Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units

Critical Care Medicine

Volumn 38, Issue 9, 2010, Pages 1890-1898

  Kanji, Salmaan ^a,b   Lam, Jason ^a   Johanson, Christel ^a   Singh, Avinder ^a   Goddard, Rob ^a   Fairbairn, Jennifer ^a   Lloyd, Tammy ^a   Monsour, Danny ^b   Kakal, Juzer ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

chemical compatibility; drug infusions; intensive care unit; physical compatibility

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; AMIODARONE; ARGATROBAN; CALCIUM CHLORIDE; CISATRACURIUM; DANAPAROID; DILTIAZEM; DOBUTAMINE; DOPAMINE; DROTRECOGIN; ESMOLOL; FENTANYL; FUROSEMIDE; GLUCONATE CALCIUM; GLYCERYL TRINITRATE; HEPARIN; HYDROMORPHONE; INSULIN; KETAMINE; LABETALOL; LORAZEPAM; MAGNESIUM SULFATE; MANNITOL; METOPROLOL; MIDAZOLAM; MILRINONE; MORPHINE; NITROPRUSSIDE SODIUM; UNINDEXED DRUG;

CONTINUOUS INFUSION; HUMAN; INTENSIVE CARE UNIT; OBSERVER BIAS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; DRUG INTERACTION; DRUG STABILITY; INTRAVENOUS DRUG ADMINISTRATION;

DRUG INTERACTIONS; DRUG STABILITY; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS;

EID: 77956229779     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181e8adcc     Document Type: Review

References (105)

1. Kohut J III, Trissel LA, Leissing NC: Don't ignore details of drug-compatibility reports. Am J Health Syst Pharm 1996; 53:2339.
2. Trissel LA: Everything in a compatibility study is important. Am J Health Syst Pharm 1996; 53:2990.
3. Newton DW: Drug incompatibility chemistry. Am J Health Syst Pharm 2009; 66: 348-357.
4. Maki DG, Kluger DM, Crnich CJ: The risk of bloodstream infection in adults with different intravascular devices: A systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159-1171.
5. McGee DC, Gould MK: Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123-1133.
6. Merrer J, De Jonghe B, Golliot F, et al: Complications of femoral and subclavian venous catheterization in critically ill patients: A randomized controlled trial. JAMA 2001; 286:700-707.
7. Kanji S, Lam J, Goddard RD, et al: Crosssectional observational study of continuously infused medication administration practices and venous access devices in Canadian adult ICU patients. Crit Care Med 2008; 36(Suppl):A94.
8. Trissel LA: Avoiding common flaws in stability and compatibility studies of injectable drugs. Am J Hosp Pharm 1983; 40: 1159-1160.
9. Trissel LA, Flora KP: Stability studies: Five years later. Am J Hosp Pharm 1988; 45: 1569-1571.
10. Akkerman SR, Zhang H, Mullins RE, et al: Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health Syst Pharm 1999; 56:63-68.
11. Allen LV Jr, Levinson RS, Phisutsinthop D: Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm 1977; 34:939-943.
12. Allen LV Jr, Stiles ML: Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Part. Am J Hosp Pharm 1981; 38:380-381.
13. Ambados F, Brealey J: Compatibility of ketamine hydrochloride and fentanyl citrate in polypropylene syringes. Am J Health Syst Pharm 2004; 61:1438, 1445.
14. Athanikar N, Boyer B, Deamer R, et al: Visual compatibility of 30 additives with a parenteral nutrient solution. Am J Hosp Pharm 1979; 36:511-513.
15. Baaske DM, Dykstra SD, Wagenknecht DM, et al: Stability of esmolol hydrochloride in intravenous solutions. Am J Hosp Pharm 1994; 51:2693-2696.
16. Baker DE, Yost GS, Craig VL, et al: Compatibility of heparin sodium and morphine sulfate. Am J Hosp Pharm 1985; 42: 1352-1355.
17. Baptista RJ, Dumas DJ, Bistrian BR, et al: Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985; 42:777-778.
18. Barker B, Feddema S, Rusho WJ, et al: Visual compatibility of vasopressin with other injectable drugs. Am J Health Syst Pharm 2005; 62:1969, 1975-1976.
19. Bhatt-Mehta V, Nahata MC: Stability of dopamine hydrochloride injection in the presence of dobutamine hydrochloride, tolazoline hydrochloride, and theophylline injections. J Perinatol 1990; 10:129-133.
20. Bhatt-Mehta V, Rosen DA, King RS, et al: Stability of midazolam hydrochloride in parenteral nutrient solutions. Am J Hosp Pharm 1993; 50:285-288.
21. Bhatt-Mehta V, Paglia RE, Rosen DA: Stability of propofol with parenteral nutrient solutions during simulated Y-site injection. Am J Health Syst Pharm 1995; 52:192-196.
22. Bhatt-Mehta V, Johnson CE, Leininger N, et al: Stability of fentanyl citrate and midazolam hydrochloride during simulated intravenous coadministration. Am J Health Syst Pharm 1995; 52:511-513.
23. Campbell S, Nolan PE Jr, Bliss M, et al: Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986; 43:917-921.
24. Chalmers JR, Bobek MB, Militello MA: Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health Syst Pharm 2001; 58: 504-506.
25. Chandler SW, Trissel LA, Weinstein SM: Combined administration of opioids with selected drugs to manage pain and other cancer symptoms: Initial safety screening for compatibility. J Pain Symptom Manage 1996; 12:168-171.
26. Chernin EL, Stewart JT, Smiler B: Stability of thiopental sodium and propofol in polypropylene syringes at 23 and 4 degrees C. Am J Health Syst Pharm 1996; 53: 1576-1579.
27. Chiu MF, Schwartz ML: Visual compatibility of injectable drugs used in the intensive care unit. Am J Health Syst Pharm 1997; 54:64-65.
28. Cohen MH, Johnston-Early A, Hood MA, et al: Drug precipitation within IV tubing: A potential hazard of chemotherapy administration. Cancer Treat Rep 1985; 69: 1325-1326.
29. Colucci RD, Cobuzzi LE, Halpern NA: Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988; 45:1357-1358.
30. Colucci RD, Cobuzzi LE, Halpern NA: Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988; 45:630-632.
31. Cutie MR: Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981; 38:231.
32. Cutie MR: Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983; 40: 1205-1207.
33. Dahlin PA, Paredes SM: Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980; 37:460, 464.
34. Das G V, Stewart KR: Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5% dextrose injections. Am J Hosp Pharm 1984; 41:686-689.
35. Dasta JF, Hale KN, Stauffer GL, et al: Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs. Am J Hosp Pharm 1988; 45:2361-2366.
36. Faria CE, Fiumara K, Patel N, et al: Visual compatibility of furosemide with phenylephrine and vasopressin. Am J Health Syst Pharm 2006; 63:906-908.
37. Feddema S, Rusho WJ, Tyler LS, et al: Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health Syst Pharm 2003; 60: 1271-1272.
38. Forman JK, Souney PF: Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987; 44:2298-2299.
39. Gardella LA, Zaroslinski JF, Possley LH: Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 1: Stability with common intravenous fluids. Am J Hosp Pharm 1975; 32:575-578.
40. Gardella LA, Kesler H, Amann A, et al: Intropin (dopamine hydrochloride) intravenous admixture compatibility, Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978; 35:581-584.
41. Gayed AA, Keshary PR, Hinkle RL: Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health Syst Pharm 1995; 52:516-520.
42. Grant HR: Compatibilities of intravenous admixtures. Hospital Pharmacist 1962; 15: 67-70, 94.
43. Hadzija BW, Lubarsky DA: Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health Syst Pharm 1995; 52:997-999.
44. Hartman CA, Baroletti SA, Churchill WW, et al: Visual compatibility of argatroban with selected drugs. Am J Health Syst Pharm 2002; 59:1784-1785.
45. Hasegawa GR, Eder JF: Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984; 41:1379-1380.
46. Hasegawa GR, Eder JF: Dobutamine-heparin mixture inadvisable. Am J Hosp Pharm 1984; 41:2588, 2590.
47. Hasegawa GR, Eder JF: Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984; 41:949-951.
48. Hassan E, Leslie J, Martir-Herrero ML: Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994; 51:2143-2145.
49. Henann NE, Jacks TT Jr: Compatibility and availability of sodium bicarbonate in total parenteral nutrient solutions. Am J Hosp Pharm 1985; 42:2718-2720.
50. Honisko ME, Fink JM, Militello MA, et al: Compatibility of argatroban with selected cardiovascular agents. Am J Health Syst Pharm 2004; 61:2415-2418.
51. Johnson CE, Bhatt-Mehta V, Mancari SC, et al: Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration. Am J Hosp Pharm 1994; 51:2812-2815.
52. Karnatz NN, Wong J, Kesler H, et al: Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration. Am J Hosp Pharm 1988; 45:368-371.
53. Karnatz NN, Wong J, Baaske DM, et al: Stability of esmolol hydrochloride and sodium nitroprusside in intravenous admixtures. Am J Hosp Pharm 1989; 46:101-104.
54. Kershaw BP, Monnier HL, Mason JH: Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993; 50:1360, 1362-1363.
55. Kirschenbaum HL, Aronoff W, Piltz GW, et al: Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983; 40:1690-1691.
56. Klamerus KJ, Ueda CT, Newton DW: Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984; 41:303-305.
57. Korth-Bradley JM, Ludwig S: Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections. Am J Health Syst Pharm 1995; 52:2340.
58. La Forgia SP, Sharley NA, Burgess NG, et al: Stability and compatibility of morphine, midazolam and bupivicaine combinations for intravenous infusion. J Pharm Pract Res 2002; 32:65-68.
59. Lau MH, Hackman C, Morgan DJ: Compatibility of ketamine and morphine injections. Pain 1998; 75:389-390.
60. Letourneau M, Milot L, Souney PF: Visual compatibility of magnesium sulfate with narcotic analgesics. Am J Hosp Pharm 1992; 49:838-839.
61. Macias JM, Martin WJ, Lloyd CW: Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation. Am J Hosp Pharm 1985; 42:1087-1094.
62. Mann HJ, Demmon SL, Boelk DA, et al: Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. Am J Health Syst Pharm 2004; 61:2664-2671.
63. Mantong ML, Marquardt ED: Visual com-patibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health Syst Pharm 1995; 52: 2567-2568.
64. Marquardt ED, Lam SS: Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994; 51:811-812.
65. Matthew D, Groutas WC: In vitro study of the effect of selected drugs used in carrier intravenous lines on sodium nitroprusside delivery. Heart Lung 1984; 13:645-649.
66. Matuschka PR, Smith WR, Vissing RS: Compatibility of mannitol and sodium bicarbonate in injectable fluids. Am J Health Syst Pharm 1995; 52:320-321.
67. Michaels MR, Stauffer GL, Haas DP: Propofol compatibility with other intravenous drug products: Two new methods of evaluating IV emulsion compatibility. Ann Pharmacother 1996; 30:228-232.
68. Moshfeghi M, Ciuffo JD: Visual compatibility of fentanyl citrate with parenteral nutrient solutions. Am J Health Syst Pharm 1998; 55:1194, 1197.
69. Negro S, Azuara ML, Sanchez Y, et al: Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2002; 10:65-70.
70. Newland AM, Mauro VF, Alexander KS: Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents. Am J Health Syst Pharm 2009; 66: 986-987.
71. Palmquist KL, Quattrocchi FP, Looney LA: Compatibility of furosemide with 20% mannitol. Am J Health Syst Pharm 1995; 52: 648, 650.
72. Pelletier E, Forest J-M, Hildgen P: Compatibilite de la ketamine injectable lors de l'administration en derive avec d'autres medicament usuels. Pharmactuel 2006; 39: 71-75.
73. Pere H, Chasse V, Forest J-M, et al: Compatibilite du pantoprazole injectable lors d'administration en Y. Pharmactuel 2004; 37:193-196.
74. Pereira-Rosario R, Utamura T, Perrin JH: Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry. Am J Hosp Pharm 1988; 45:1350-1352.
75. Prankerd RJ, Jones RD: Physicochemical compatibility of propofol with thiopental sodium. Am J Health Syst Pharm 1996; 53:2606-2610.
76. Pugh CB, Pabis DJ, Rodriguez C: Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991; 48:123-125.
77. Riley BB: Incompatibilities in intravenous solutions. J Hosp Pharm 1970; 28:228-240.
78. Riley CM: Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988; 45:2079-2091.
79. Ritchie DJ, Holstad SG, Westrich TJ, et al: Activity of octreotide acetate in a total nutrient admixture. Am J Hosp Pharm 1991; 48:2172-2175.
80. Schaaf LJ, Robinson DH, Vogel GJ, et al: Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm 1990; 47: 1567-1571.
81. Schmid R, Koren G, Klein J, et al: The stability of a ketamine-morphine solution. Anesth Analg 2002; 94:898-900, table.
82. Selam JL, Lord P, Van Antwerp WP, et al: Heparin addition to insulin in implantable pumps to prevent catheter obstruction. Diabetes Care 1989; 12:38-39.
83. Seto W, Trope A, Carfrae L, et al: Visual compatibility of sodium nitroprusside with other injectable medications given to pediatric patients. Am J Health Syst Pharm 2001; 58:1422-1426.
84. Smythe M, Malouf E: Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991; 48: 125-126.
85. Smythe MA, Patel MA, Gasloli RA: Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990; 47:819-820.
86. Swart EL, Mooren RA, van Loenen AC: Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 1995; 52:2020-2022.
87. Thompson DF, Thompson GD: Visual compatibility of esmolol hydrochloride and furosemide in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm 1987; 44:2740.
88. Thompson M, Smith M, Gragg R, et al: Stability of nitroglycerin and dobutamine in 5% dextrose and 0.9% sodium chloride injection. Am J Hosp Pharm 1985; 42: 361-362.
89. Trissel LA, Martinez JF, Gilbert DL Jr: Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 1997; 54:1735-1741.
90. Trissel LA, Gilbert DL, Martinez JF, et al: Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 1997; 54:1295-1300.
91. Trissel LA, Gilbert DL, Martinez JF: Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 1997; 54:1287-1292.
92. Trissel LA, Gilbert DL, Martinez JF, et al: Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr 1999; 23:67-74.
93. Trissel LA: Drug compatibility differences with propofol injectable emulsion products. Crit Care Med 2001; 29:466-468.
94. Veltri M, Lee CK: Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health Syst Pharm 1996; 53:2611-2613.
95. Veltri MA, Conner KG: Physical compatibility of milrinone lactate injection with intravenous drugs commonly used in the pediatric intensive care unit. Am J Health Syst Pharm 2002; 59:452-454.
96. Vogt C, Skipper PM, Ruggaber S: Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection. Am J Hosp Pharm 1993; 50:2311.
97. Walker S, Fan-Lun C, Wyllie A, et al: Physical compatibility of pantoprazole with selected medications during simulated y-site administration. Can J Hosp Pharm 2004; 57:90-97.
98. Wilson KM, Schneider JJ, Ravenscroft PJ: Stability of midazolam and fentanyl in infusion solutions. J Pain Symptom Manage 1998; 16:52-58.
99. Wilson TD, Forde MD: Stability of milrinone and epinephrine, atropine sulfate, lidocaine hydrochloride, or morphine sulfate injection. Am J Hosp Pharm 1990; 47: 2504-2507.
100. Yamashita SK, Walker SE, Choudhury T, et al: Compatibility of selected critical care drugs during simulated Y-site administration. Am J Health Syst Pharm 1996; 53: 1048-1051.
101. Yuen PH, Taddei CR, Wyka BE, et al: Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. Am J Hosp Pharm 1983; 40: 1007-1009.
102. Zanetti LA: Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992; 49:1911.
103. Hill SE, Heldman LS, Goo ED, et al: Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr 1996; 20:81-87.
104. Taniguchi T, Yamamoto K, Kobayashi T: Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. Can J Anaesth 1998; 45:347-351.
105. Grillo JA, Barie PS: Precipitation of lorazepam during infusion by volumetric pump. Am J Health Syst Pharm 1996; 53:1850